| Project/Area Number |
07671423
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
TSUNODA Akira Showa University, School of Medicine, Lecturer, 医学部, 講師 (10183485)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIBUSAWA Miki Showa University, School of Medicine, Associate Professor, 医学部, 助教授 (90138496)
|
|---|
| Project Period (FY) |
1995 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1997: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1996: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1995: ¥600,000 (Direct Cost: ¥600,000)
|
|---|
| Keywords | Colon Cancer / Chemical-induced / Anticancer agent / in vivo screening / tumor doubling time / tumor doubleing time |
|---|
| Research Abstract |
(1) Thirty-four Sprague-Dawley rats received dimetyl-hydrazine (40 mg/kg) s.c. once weekly for 10 weeks to induce colon cancer. Twenty weeks after begining the carcinogen treatment, a barium enema was performed to determine the size of colon tumors. The animals were divided into CDDP group and CPT-11 group, in which the maximum tolerable dose of each drug was given. After 5 weeks of treatment, the barium enema was repeated. "Response" was assessed on the basis of tumor doubling time. Response rates in the CDDP and CPT-11 groups were 6% and 35%, respectively.
(2) Thirty-four Sprague-Dawley rats received azoxymethane (7.4 mg/kg) s.c. once weekly for 10 weeks to induce colon cancer. Same technique as mentioned above was used throughout. The animals were divided into three groups, which were subjected to the following treatment : control group, UFT group, and UFT plus CDDP group.
The response rates in the UFT and the UFT plus CDDP groups were 25% and 50%, respectively.
(3) These results reflect the clinical data of those drugs or the combined treatment. The present experimental system may be a predictive model for screening anticancer drugs.
|
